Rich Adcock retweeted
ImmunityBio has received marketing authorization in the United Arab Emirates for ANKTIVA® with BCG across two indications: BCG-unresponsive non-muscle invasive bladder cancer with CIS with or without papillary tumors and BCG-unresponsive non-muscle invasive bladder cancer with papillary tumors, and metastatic non-small cell lung cancer. This authorization expands our global regulatory footprint to 34 countries and marks another important step in broadening access to innovative immunotherapy options for patients worldwide.
Learn more: immunitybio.com/immunitybio-…
Rich Adcock retweeted
At the heart of every advancement are the people who make it possible.
Our focus is on bringing in individuals who are collaborative, solution-oriented, and motivated by work that carries broader significance. View our open roles: immunitybio.com/careers/
Rich Adcock retweeted
At #AUA2026, our Founder, Executive Chairman and Global Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong, took center stage to address several of the most pressing challenges facing the bladder cancer community today: the continued impact of BCG shortages and ImmunityBio's efforts to help advance new supply solutions to the broader need for sustainable innovation across the field.
The discussion reinforced an important reality: progressing bladder cancer care requires more than scientific progress alone. It also demands long-term commitment, collaboration, and practical solutions that help ensure patients can reliably access the therapies they need. – at Washington, DC
Rich Adcock retweeted
Great chatting with @UroDocAsh at AUA26 in Washington DC with @urotoday. Always a pleasure to talk about the patients and expanding access to drugs for all. Duration matters, not just the initial CR. We addressed key issues and agreed that CIS and papillary are the same disease. – at Washington, DC
Rich Adcock retweeted
ImmunityBio has announced an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory for the development and commercialization of Tokyo strain BCG in the U.S.
Today's announcement marks a notable step forward in addressing the ongoing BCG shortage that has impacted urologists and bladder cancer patients for more than a decade.
Learn more: immunitybio.com/immunitybio-…
Rich Adcock retweeted
Bladder cancer remains a persistent challenge in oncology, demanding meaningful innovation.
Through a multi-faceted approach to immunotherapy, ImmunityBio is focused on redefining how this disease is treated - grounded in science, guided by patients, and driven by our mission.
This Bladder Cancer Awareness Month, we recognize the resilience of patients, the support of caregivers, and the guidance of healthcare providers who continue to push progress forward. Learn more about our work: immunitybio.com/bladder-canc…
Rich Adcock retweeted
This weekend, we joined the @BladderCancerUS (BCAN) Walk in Los Angeles, coming together with a community united by strength, resilience, and shared purpose.
Every step reflects the ongoing journey faced by those impacted by bladder cancer and the collective commitment to raising awareness and supporting one another along the way.
Get involved in a walk near you: bcan.org/why-i-walk-to-end-b…
Rich Adcock retweeted
Access to innovative cancer therapies continues to expand. ANKTIVA® is now available in Saudi Arabia for patients with bladder and lung cancers, marking an important step in ImmunityBio’s global efforts to reach more patients.
Read more: immunitybio.com/immunitybio-…
Rich Adcock retweeted
Great meetings today. Transforming cancer globally at scale. @ClevelandClinic
Rich Adcock retweeted
Replying to @DrPatrick @ClevelandClinic
Welcome to our home , happy to welcome you and @richadcock as our partners in bladder cancer innovation
Rich Adcock retweeted
This World Health Day, we're reminded that progress in healthcare requires continued innovation.
Our work centers on developing immune-based approaches designed to address areas of ongoing unmet need in cancer care. View our pipeline: immunitybio.com/pipeline/
Rich Adcock retweeted
The amazing dedicated team at CSSIFM treating our cancer patients with NK cells in clinical trials. So many requests from patients who have failed all standards of care and they are working so hard to file for FDA authorization as many single patient INDs as we can. Happy Easter and stay safe
Rich Adcock retweeted
Glioblastoma is not only among the most common malignant brain tumors - it is also one of the most aggressive and difficult to treat.
Advancing care requires new approaches.
Learn more about how we are exploring the potential of the immune system to enhance how the body identifies and responds to cancers such as glioblastoma: immunitybio.com/glioblastoma…
Rich Adcock retweeted
According to the American Cancer Society's 2026 Facts & Figures, bladder cancer remains a significant burden for patients, underscoring the urgent need for more effective and patient-centered treatment options.
At ImmunityBio, we're focused on reducing the burden of care while advancing meaningful solutions.
Rich Adcock retweeted
A step forward in global expansion: ANKTIVA® (nogapendekin alfa inbakicept-pmln) has received regulatory approval in Macau SAR, China for patients with BCG-unresponsive NMIBC ± CIS papillary tumors.
Explore the full announcement: immunitybio.com/immunitybio-…
Rich Adcock retweeted
Global expansion-first approval in Asia!! Anktiva now approved in Macau, China today. Paradigm change of treating the immune system unstoppable.
Rich Adcock retweeted
Great announcement today by HHS and NCI to support cancer vaccine trials. We have spent the past decade collaborating with 2 amazing thought leaders at the National Cancer Institute (NCI) in the field of cancer vaccine, Dr James Gulley and Dr Jeffrey Schlom.
Together we have completed Phase 1 & 2 trials across multiple tumor types showing how our Adeno vaccine plus Anktiva generates tumor specific T cells. The randomized trial to PREVENT cancer in subjects with Lynch Syndrome which affects over a million Americans (1 in 278) is fully enrolled and the early data so far shows that Anktiva and the Adeno vaccine increases NK and T cells in these subjects, even in subjects aged 65
wsj.com/articles/hhs-has-a-p…
Rich Adcock retweeted
The NCCN® Clinical Practice Guidelines now include ANKTIVA® plus BCG for patients with BCG-unresponsive NMIBC with papillary-only disease.
This update reflects continued progress in expanding treatment considerations for patients facing limited options following BCG therapy. Learn more: immunitybio.com/immunitybio-…
Rich Adcock retweeted
We’ve announced a milestone in large-scale production and cryopreservation of memory cytokine-enhanced natural killer (NK) cells from more than 60 healthy and cancer donors, supporting ongoing research in NK cell–based therapies.
Read more:
immunitybio.com/immunitybio-…












